Research advances in primary biliary cholangitis
10.3760/cma.j.issn.1007-3418.2017.11.001
- VernacularTitle: 原发性胆汁性胆管炎研究进展
- Author:
Weijia DUAN
1
;
Jidong JIA
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University; Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis; National Clinical Research Center for Digestive Disease, Beijing 100050, China.
- Publication Type:Editorial
- Keywords:
Diagnosis;
Therapy;
Primary biliary cholangitis
- From:
Chinese Journal of Hepatology
2017;25(11):801-804
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is a chronic cholestatic disease with unknown pathogenesis. Positive anti-mitochondrial antibody has high sensitivity and specificity in the diagnosis of this disease. Ursodeoxycholic acid is mainly used for the treatment of PBC, but 40% of patients have an unsatisfactory biochemical response to this drug. 6-Ethylchenodeoxycholic acid is a new drug approved for the treatment of PBC, and liver transplantation remains the only effective method for the treatment of patients with end-stage PBC.
